You can manage bookmarks using lists, please log in to your user account for this.
Media type:
E-Article
Title:
The Current Status of Granulocyte-Colony Stimulating Factor to Treat Acute-on-Chronic Liver Failure
Contributor:
Engelmann, Cornelius;
Martino, Vincent Di;
Kerbert, Annarein J.C.;
Weil-Verhoeven, Delphine;
Aehling, Niklas Friedemann;
Herber, Adam;
Thévenot, Thierry;
Berg, Thomas
imprint:
Georg Thieme Verlag KG, 2021
Published in:Seminars in Liver Disease
Language:
English
DOI:
10.1055/s-0041-1723034
ISSN:
0272-8087;
1098-8971
Origination:
Footnote:
Description:
<jats:title>Abstract</jats:title><jats:p>Patients with acute-on-chronic liver failure (ACLF) have a devastating prognosis and therapeutic options are limited. Granulocyte-colony stimulating factor (G-CSF) mobilizes immune and stem cells and possess immune-modulatory and proregenerative capacities. In this review, we aim to define the current evidence for the treatment with G-CSF in end-stage liver disease. Several smaller clinical trials in patients with different severity grades of end-stage liver disease have shown that G-CSF improves survival and reduces the rate of complications. Adequately powered multicenter European trials could not confirm these beneficial effects. In mouse models of ACLF, G-CSF increased the toll-like receptor (TLR)-mediated inflammatory response which led to an increase in mortality. Adding a TLR4 signaling inhibitor allowed G-CSF to unfold its proregenerative properties in these ACLF models. These data suggest that G-CSF requires a noninflammatory environment to exert its protective properties.</jats:p>